

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: C07D 401/06, 471/10, 401/14, 405/14, 409/14, A61K 31/445 // (C07D 471/10, 235:00, 221:00)	A1	(11) International Publication Number: WO 94/26735 (43) International Publication Date: 24 November 1994 (24.11.94)
(21) International Application Number: PCT/US94/04498 (22) International Filing Date: 22 April 1994 (22.04.94) (30) Priority Data: 08/058,606 6 May 1993 (06.05.93) US 08/218,483 28 March 1994 (28.03.94) US 08/225,371 19 April 1994 (19.04.94) US (71) Applicant: MERRELL DOW PHARMACEUTICALS INC. [US/US]; 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US). (71)(72) Applicants and Inventors: BURKHOLDER, Timothy, P. [US/US]; 452 Vinnedge Avenue, Fairfield, OH 45014 (US). LE, Tieu-Binh [US/US]; 10 E. Lakeshore Drive, #18, Cincinnati, OH 45237 (US). KUDLACZ, Elizabeth, M. [US/US]; 10856 Lake Thames, Cincinnati, OH 45242 (US). MAYNARD, George, D. [US/US]; 9214 Hunters Creek Drive, Apartment C, Cincinnati, OH 45242 (US). (74) Agent: COLLIER, Kenneth, J.; Marion Merrell Dow Inc., 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US).	(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i>	
(54) Title: SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS		
(57) Abstract <p>The present invention relates to substituted pyrrolidinyl-3-yl-alkyl-piperidines, their stereoisomers, and pharmaceutically acceptable salts thereof and processes for preparation of the same. The compounds of the present invention are useful in their pharmacological activities such as tachykinin antagonism, especially substance P and neurokinin A antagonism, and the like. Compounds having the property of tachykinin antagonism are indicated for conditions associated with neurogenic inflammation and other diseases described herein.</p>		